nivolumab,DF6002
bms,Dragonfly
['nivo', 'nivolumab']
our paper is out in cell press' med! preclinical data in support of our novel il-12 cytokine immunotherapy, currently in phase 1 with dose escalation in patients (as a monotherapy &amp; in combination with nivolumab) in the u.s. &amp; europe #aacr23 #aacr2023. 
We are a clinical-stage company developing drugs targeting natural killer cells & other cells of the innate immune system, to eliminate cancer & other diseases.